中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
28期
128-129
,共2页
培美曲塞%吉非替尼%肺癌脑转移
培美麯塞%吉非替尼%肺癌腦轉移
배미곡새%길비체니%폐암뇌전이
Pemetrexed%The treatment for%Brain metastases from lung cancer
目的 对靶向药物治疗肺癌脑转移的效果进行分析探讨.方法 整群选取该院2014年1月—2015年1月收治的66例肺癌脑转移患者,随机分为对照组和观察组,对照组33例患者行培美曲塞联合卡莫司汀治疗,观察组33例患者以吉非替尼治疗,对比两组患者的治疗效果及不良反应发生率. 结果 观察组的治疗有效率为57.58%,对照组的治疗有效率为24.24%,观察组的治疗有效率明显高于对照组,P<0.05,差异具有统计学意义. 两组患者的不良反应的发生率比较,差异无统计学意义(P>0.05).结论 对肺癌脑转移患者采用吉非替尼治疗可有效提高治疗效果,降低不良反应的发生率,值得临床推广借鉴.
目的 對靶嚮藥物治療肺癌腦轉移的效果進行分析探討.方法 整群選取該院2014年1月—2015年1月收治的66例肺癌腦轉移患者,隨機分為對照組和觀察組,對照組33例患者行培美麯塞聯閤卡莫司汀治療,觀察組33例患者以吉非替尼治療,對比兩組患者的治療效果及不良反應髮生率. 結果 觀察組的治療有效率為57.58%,對照組的治療有效率為24.24%,觀察組的治療有效率明顯高于對照組,P<0.05,差異具有統計學意義. 兩組患者的不良反應的髮生率比較,差異無統計學意義(P>0.05).結論 對肺癌腦轉移患者採用吉非替尼治療可有效提高治療效果,降低不良反應的髮生率,值得臨床推廣藉鑒.
목적 대파향약물치료폐암뇌전이적효과진행분석탐토.방법 정군선취해원2014년1월—2015년1월수치적66례폐암뇌전이환자,수궤분위대조조화관찰조,대조조33례환자행배미곡새연합잡막사정치료,관찰조33례환자이길비체니치료,대비량조환자적치료효과급불량반응발생솔. 결과 관찰조적치료유효솔위57.58%,대조조적치료유효솔위24.24%,관찰조적치료유효솔명현고우대조조,P<0.05,차이구유통계학의의. 량조환자적불량반응적발생솔비교,차이무통계학의의(P>0.05).결론 대폐암뇌전이환자채용길비체니치료가유효제고치료효과,강저불량반응적발생솔,치득림상추엄차감.
Objective To targeted drugs for the treatment of lung cancer with brain metastasis were analyzed. Methods From Jan-uary 2014 to January 2015, 66 cases of patients with brain metastases from lung cancer were randomly divided into control group and observation group, control group 33 cases patients pemetrexed combined comer west treatment, observation of the treatment group of 33 patients with treatment, compared two groups of patients with the treatment effects, and the incidence of adverse reac-tions. Results The treatment group effective rate was 57.58%, the control group treatment effective rate was 24.24%, the efficient treatment of observation group was obviously higher than that of control group (P<0.05), the difference is statistically significant. The incidence rate of adverse reaction of two groups of patients have no significant difference (P>0.05). Conclusion For the treat-ment of patients with brain metastases from lung cancer using treatment can effectively improve the treatment effect, reduce the in-cidence of adverse reactions, is worthy of reference for clinical promotion.
